RU2012106116A - Вариантные формы уратоксидазы и их применение - Google Patents
Вариантные формы уратоксидазы и их применение Download PDFInfo
- Publication number
- RU2012106116A RU2012106116A RU2012106116/10A RU2012106116A RU2012106116A RU 2012106116 A RU2012106116 A RU 2012106116A RU 2012106116/10 A RU2012106116/10 A RU 2012106116/10A RU 2012106116 A RU2012106116 A RU 2012106116A RU 2012106116 A RU2012106116 A RU 2012106116A
- Authority
- RU
- Russia
- Prior art keywords
- uricase
- amino acid
- shortened
- isolated
- mammalian
- Prior art date
Links
- 108010092464 Urate Oxidase Proteins 0.000 claims abstract 41
- 150000001413 amino acids Chemical class 0.000 claims abstract 24
- 235000001014 amino acid Nutrition 0.000 claims abstract 18
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract 10
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract 10
- 238000006467 substitution reaction Methods 0.000 claims abstract 10
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract 8
- 239000004473 Threonine Substances 0.000 claims abstract 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims abstract 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract 4
- 229920000642 polymer Polymers 0.000 claims abstract 4
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims abstract 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims abstract 2
- 239000004471 Glycine Substances 0.000 claims abstract 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims abstract 2
- 239000004472 Lysine Substances 0.000 claims abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract 2
- 235000004279 alanine Nutrition 0.000 claims abstract 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims abstract 2
- 229930182817 methionine Natural products 0.000 claims abstract 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims abstract 2
- 238000004904 shortening Methods 0.000 claims abstract 2
- 235000018102 proteins Nutrition 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12N9/0048—Uricase (1.7.3.3)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
1. Конъюгат уриказы, содержащий изолированную укороченную уриказу млекопитающего, которая укорочена с аминоконца на 6 аминокислот и дополнительно содержит аминокислотную замену на треонин в положении 46 (S46T), аминокислотную замену на треонин в положении 7 (D7T), аминокислотную замену на лизин в положении 291 (R291K) и аминокислотную замену на серин в положении 301 (T301S), где указанное укорочение и аминокислотная замена относятся к неукороченной уриказе свиньи, имеющей аминокислотную последовательность SEQ ID NO: 11,где уриказа конъюгирована с полимером.2. Конъюгат уриказы по п.1, в котором изолированная укороченная уриказа млекопитающего дополнительно содержит аминоконцевую аминокислоту, где аминоконцевой аминокислотой является аланин, глицин, пролин, серин или треонин.3. Конъюгат уриказы по п.2, в котором концевой аминокислотой является треонин.4. Конъюгат уриказы по п.1, в котором изолированная укороченная уриказа млекопитающего состоит из аминокислотной последовательности SEQ ID NO: 8.5. Конъюгат уриказы по п.4, в котором белок изолированной укороченной уриказы млекопитающего дополнительно содержит N-концевую аминокислоту, где N-концевой аминокислотой является метионин.6. Конъюгат уриказы по п.5, в котором изолированная укороченная уриказа млекопитающего состоит из аминокислотной последовательности SEQ ID NO: 7.7. Конъюгат уриказы по любому из пп.1-6, в котором полимер представляет собой полиэтиленгликоль.8. Конъюгат уриказы по п.7, содержащий от 2 до 12 молекул полиэтиленгликоля на каждую субъединицу уриказы.9. Конъюгат уриказы по п.8, содержащий от 3 до 10 молекул полиэтиленгликоля на каждую субъединицу уриказы.10. Конъюгат уриказы по п.7,
Claims (13)
1. Конъюгат уриказы, содержащий изолированную укороченную уриказу млекопитающего, которая укорочена с аминоконца на 6 аминокислот и дополнительно содержит аминокислотную замену на треонин в положении 46 (S46T), аминокислотную замену на треонин в положении 7 (D7T), аминокислотную замену на лизин в положении 291 (R291K) и аминокислотную замену на серин в положении 301 (T301S), где указанное укорочение и аминокислотная замена относятся к неукороченной уриказе свиньи, имеющей аминокислотную последовательность SEQ ID NO: 11,
где уриказа конъюгирована с полимером.
2. Конъюгат уриказы по п.1, в котором изолированная укороченная уриказа млекопитающего дополнительно содержит аминоконцевую аминокислоту, где аминоконцевой аминокислотой является аланин, глицин, пролин, серин или треонин.
3. Конъюгат уриказы по п.2, в котором концевой аминокислотой является треонин.
4. Конъюгат уриказы по п.1, в котором изолированная укороченная уриказа млекопитающего состоит из аминокислотной последовательности SEQ ID NO: 8.
5. Конъюгат уриказы по п.4, в котором белок изолированной укороченной уриказы млекопитающего дополнительно содержит N-концевую аминокислоту, где N-концевой аминокислотой является метионин.
6. Конъюгат уриказы по п.5, в котором изолированная укороченная уриказа млекопитающего состоит из аминокислотной последовательности SEQ ID NO: 7.
7. Конъюгат уриказы по любому из пп.1-6, в котором полимер представляет собой полиэтиленгликоль.
8. Конъюгат уриказы по п.7, содержащий от 2 до 12 молекул полиэтиленгликоля на каждую субъединицу уриказы.
9. Конъюгат уриказы по п.8, содержащий от 3 до 10 молекул полиэтиленгликоля на каждую субъединицу уриказы.
10. Конъюгат уриказы по п.7, в котором каждая молекула полиэтиленгликоля имеет молекулярную массу от 1 кДа до 100 кДа.
11. Конъюгат уриказы по п.10, в котором каждая молекула полиэтиленгликоля имеет молекулярную массу от 1 кДа до 50 кДа.
12. Конъюгат уриказы по п.11, в котором каждая молекула полиэтиленгликоля имеет молекулярную массу от 5 кДа до 20 кДа.
13. Конъюгат уриказы по п.12, в котором каждая молекула полиэтиленгликоля имеет молекулярную массу приблизительно 10 кДа.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67057305P | 2005-04-11 | 2005-04-11 | |
| US60/670,573 | 2005-04-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007141625/10A Division RU2451074C2 (ru) | 2005-04-11 | 2006-04-11 | Вариантные формы уратоксидазы и их применение |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2012106116A true RU2012106116A (ru) | 2013-08-27 |
| RU2610680C2 RU2610680C2 (ru) | 2017-02-14 |
| RU2610680C9 RU2610680C9 (ru) | 2018-05-30 |
Family
ID=37075495
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007141625/10A RU2451074C2 (ru) | 2005-04-11 | 2006-04-11 | Вариантные формы уратоксидазы и их применение |
| RU2012106150/10A RU2012106150A (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
| RU2012106116A RU2610680C9 (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
| RU2012106148/10A RU2012106148A (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007141625/10A RU2451074C2 (ru) | 2005-04-11 | 2006-04-11 | Вариантные формы уратоксидазы и их применение |
| RU2012106150/10A RU2012106150A (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012106148/10A RU2012106148A (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
Country Status (26)
| Country | Link |
|---|---|
| US (12) | US8188224B2 (ru) |
| EP (3) | EP1871874B1 (ru) |
| JP (6) | JP2008535500A (ru) |
| KR (1) | KR20080009111A (ru) |
| CN (1) | CN101198693B (ru) |
| AU (1) | AU2006235495B2 (ru) |
| BR (1) | BRPI0612941A2 (ru) |
| CA (1) | CA2604399A1 (ru) |
| CY (1) | CY1124138T1 (ru) |
| CZ (1) | CZ2007695A3 (ru) |
| DK (1) | DK3321359T3 (ru) |
| ES (2) | ES2856881T3 (ru) |
| FR (1) | FR15C0067I2 (ru) |
| HU (2) | HU229068B1 (ru) |
| IL (1) | IL186510A (ru) |
| LT (1) | LT3321359T (ru) |
| MX (1) | MX2007012547A (ru) |
| NZ (1) | NZ562292A (ru) |
| PL (2) | PL215285B1 (ru) |
| PT (1) | PT3321359T (ru) |
| RU (4) | RU2451074C2 (ru) |
| SG (1) | SG161247A1 (ru) |
| SI (1) | SI3321359T1 (ru) |
| TW (1) | TWI366467B (ru) |
| WO (1) | WO2006110819A2 (ru) |
| ZA (1) | ZA200708650B (ru) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2158923E (pt) | 1998-08-06 | 2013-06-04 | Univ Duke | Conjugados de peg-urato oxidase e sua utilização |
| NZ562292A (en) | 2005-04-11 | 2009-11-27 | Savient Pharmaceuticals Inc | Variant forms of urate oxidase and use thereof |
| US9534013B2 (en) * | 2006-04-12 | 2017-01-03 | Horizon Pharma Rheumatology Llc | Purification of proteins with cationic surfactant |
| US20080159976A1 (en) * | 2005-04-11 | 2008-07-03 | Jacob Hartman | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
| US8148123B2 (en) * | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
| AU2006235437B2 (en) * | 2005-04-11 | 2011-11-24 | Horizon Therapeutics Usa, Inc. | A variant form of urate oxidase and use thereof |
| EP2446260B1 (en) | 2009-06-25 | 2018-12-26 | Horizon Pharma Rheumatology LLC | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| CN102051348B (zh) * | 2009-10-27 | 2012-10-03 | 重庆富进生物医药有限公司 | 人源化重组尿酸酶及其突变体 |
| WO2011127393A2 (en) | 2010-04-08 | 2011-10-13 | Georgia Tech Research Corporation | Variants of ancestral uricases and uses thereof |
| CN102634492B (zh) | 2011-02-14 | 2015-06-10 | 重庆富进生物医药有限公司 | 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用 |
| CN102260653B (zh) * | 2011-06-30 | 2013-04-03 | 荣俊 | 一种peg化重组猪-人尿酸氧化酶融合蛋白的制备及应用方法 |
| CN103834623B (zh) * | 2014-02-11 | 2017-11-07 | 中国药科大学 | 具有催化活性的人源尿酸氧化酶 |
| HK1252542A1 (zh) * | 2015-05-15 | 2019-05-31 | Medimmune, Llc | 改进的尿酸酶序列和治疗方法 |
| EP3538135A4 (en) * | 2016-11-11 | 2020-07-29 | Horizon Pharma Rheumatology LLC | POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES |
| WO2020160325A1 (en) | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| US12121566B2 (en) | 2019-01-30 | 2024-10-22 | Horizon Therapeutics Usa, Inc. | Methods for treating gout |
| WO2020228618A1 (zh) * | 2019-05-10 | 2020-11-19 | 重庆派金生物科技有限公司 | 聚乙二醇修饰的尿酸氧化酶 |
| WO2021042055A1 (en) * | 2019-08-30 | 2021-03-04 | Horizon Pharma Rheumatology Llc | Pegloticase for treatment of gout in renal transplant recipients |
| CN112646790A (zh) * | 2019-10-11 | 2021-04-13 | 上海君实生物医药科技股份有限公司 | 改进的尿酸酶及其用于治疗高尿酸血症的方法 |
| CN112980808B (zh) * | 2019-12-12 | 2024-10-29 | 深圳迈瑞生物医疗电子股份有限公司 | 尿酸酶、及其制备方法和用途 |
| CN113144174B (zh) * | 2020-01-22 | 2023-07-04 | 杭州远大生物制药有限公司 | 治疗高尿酸相关性疾病的药物 |
| EP4192581A4 (en) | 2020-08-10 | 2024-09-25 | Horizon Therapeutics USA, Inc. | METHODS OF TREATING GOUT |
| WO2022097141A1 (en) | 2020-11-03 | 2022-05-12 | Protalix Ltd. | Modified uricase and uses thereof |
| CN114438047B (zh) * | 2020-11-05 | 2024-11-22 | 重庆派金生物科技有限公司 | 制备聚乙二醇修饰的尿酸氧化酶的方法 |
| CN114438048B (zh) * | 2020-11-05 | 2024-10-22 | 重庆派金生物科技有限公司 | 尿酸氧化酶制剂及其应用 |
| CN115197923B (zh) * | 2021-04-09 | 2024-11-26 | 上海君实生物医药科技股份有限公司 | 尿酸酶、其药物组合物及其用途 |
| WO2024233370A2 (en) * | 2023-05-05 | 2024-11-14 | Insmed Incorporated | Novel uricase variants and methods of use thereof |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
| CN117230034A (zh) * | 2023-10-16 | 2023-12-15 | 临沂大学 | 一种高稳定性哺乳动物尿酸氧化酶突变体 |
Family Cites Families (162)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE279486C (ru) | ||||
| DE279489C (ru) | ||||
| US1141973A (en) | 1911-05-22 | 1915-06-08 | Jesse W Nichols | Can-cap with vent-shield. |
| DE837379C (de) | 1950-04-20 | 1955-08-16 | Nordwind G M B H | Windkraftanlage, insbesondere zum Antrieb einer Kolbenpumpe |
| US3451996A (en) | 1968-02-12 | 1969-06-24 | Thompson Farms Co | Method for the preparation of heparin |
| US3616231A (en) | 1968-11-14 | 1971-10-26 | Boehringer Mannheim Gmbh | Process for the production of uricase |
| US3613231A (en) | 1969-07-25 | 1971-10-19 | Paul F Pugh | Method for manufacturing high voltage cable systems |
| US3931399A (en) | 1970-12-22 | 1976-01-06 | Behringwerke Aktiengesellschaft | Process for isolating a fibrin-stabilizing factor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4027676A (en) | 1975-01-07 | 1977-06-07 | Ethicon, Inc. | Coated sutures |
| US4169764A (en) | 1975-08-13 | 1979-10-02 | Ajinomoto Co., Inc. | Process for production of urokinase |
| US4141973A (en) | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
| US4064010A (en) | 1976-07-21 | 1977-12-20 | Eastman Kodak Company | Purification of uricase |
| US4301153A (en) | 1977-03-21 | 1981-11-17 | Riker Laboratories, Inc. | Heparin preparation |
| US4312979A (en) | 1978-04-20 | 1982-01-26 | Toyo Soda Manufacturing Co., Ltd. | Polysaccharides containing allose |
| US4425431A (en) | 1978-04-20 | 1984-01-10 | Toyo Soda Manufacturing Co., Ltd. | Production of an allose-containing polysaccharide |
| JPS6031472B2 (ja) | 1978-12-14 | 1985-07-22 | 協和醗酵工業株式会社 | 酸性ウリカ−ゼ |
| US4251431A (en) | 1979-01-16 | 1981-02-17 | Shell Oil Company | Lubricating greases |
| JPS5599189A (en) | 1979-01-22 | 1980-07-28 | Mihama Hisaharu | Modified uricase free from antigenicity and its preparation |
| JPS55135590A (en) | 1979-04-05 | 1980-10-22 | Mihama Hisaharu | Modified asparaginase and uricase and their preparation |
| DE2916711A1 (de) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
| DE2943016C2 (de) | 1979-10-24 | 1984-09-06 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | Verfahren zur Reinigung von Interferon |
| JPS5651995A (en) | 1979-10-05 | 1981-05-09 | Green Cross Corp:The | Preparation of interferon |
| AU538665B2 (en) | 1979-10-30 | 1984-08-23 | Juridical Foundation, Japanese Foundation For Cancer Research | Human interferon dna |
| DE3005897A1 (de) | 1980-02-16 | 1981-09-03 | Hoechst Ag, 6000 Frankfurt | Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus |
| FR2475900A1 (fr) | 1980-02-20 | 1981-08-21 | Fabre Sa Pierre | Complexe vaccinal contenant un antigene specifique et vaccin le contenant |
| CH651308A5 (de) | 1980-07-01 | 1985-09-13 | Hoffmann La Roche | Interferone und deren herstellung. |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| JPS5740503A (en) | 1980-08-22 | 1982-03-06 | Seikagaku Kogyo Co Ltd | Separation of saccharides |
| US4315852A (en) | 1980-11-26 | 1982-02-16 | Schering Corporation | Extraction of interferon from bacteria |
| FR2497006A1 (fr) | 1980-12-24 | 1982-06-25 | Ind Electro Ste Gle | Contacts electriques pour cables coaxiaux et cables bifilaires |
| JPS57192435A (en) | 1981-05-20 | 1982-11-26 | Toyobo Co Ltd | Modified polypeptide |
| DE3126759A1 (de) | 1981-07-07 | 1983-01-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung |
| US4450103A (en) | 1982-03-01 | 1984-05-22 | Cetus Corporation | Process for recovering human IFN-β from a transformed microorganism |
| US4485176A (en) | 1982-06-28 | 1984-11-27 | E. I. Du Pont De Nemours & Company | Turbidimetric method for measuring protein in urine and cerebrospinal fluid |
| EP0109688A3 (en) | 1982-11-23 | 1986-12-03 | The Wellcome Foundation Limited | Improved complexes, processes for obtaining them and formulations containing such complexes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| USD279486S (en) | 1983-04-25 | 1985-07-02 | International Jensen Incorporated | Controller for a video game or the like |
| US4719179A (en) | 1984-11-30 | 1988-01-12 | Pharmacia P-L Biochemicals, Inc. | Six base oligonucleotide linkers and methods for their use |
| US4732863A (en) | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
| JPH0671425B2 (ja) | 1985-06-05 | 1994-09-14 | サッポロビール株式会社 | ウリカ−ゼおよびその製造法 |
| DE3676670D1 (de) | 1985-06-26 | 1991-02-07 | Cetus Corp | Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung. |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
| US4847079A (en) | 1985-07-29 | 1989-07-11 | Schering Corporation | Biologically stable interferon compositions comprising thimerosal |
| AU597924B2 (en) | 1985-12-11 | 1990-06-14 | Natinco Nv | Solubilization of protein aggregates |
| DD279486A1 (de) | 1986-03-10 | 1990-06-06 | Akad Wissenschaften Ddr | Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JPS6255079A (ja) | 1986-04-23 | 1987-03-10 | Mihama Hisaharu | 修飾ウリカ−ゼ |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DD279489A1 (de) | 1986-12-11 | 1990-06-06 | Leuna Werke Veb | Verfahren zur herstellung optisch transparenter epoxidharzformmassen |
| JPS63203548A (ja) | 1987-02-12 | 1988-08-23 | 四国化工機株式会社 | 飲料用密封容器の製造装置 |
| AU612133B2 (en) | 1987-02-20 | 1991-07-04 | Natinco Nv | Production of proteins in active forms |
| CA1305285C (en) | 1987-04-21 | 1992-07-14 | Malcolm Roy Brandon | Production of proteins in active forms |
| AU609824B2 (en) | 1987-06-15 | 1991-05-09 | Southern Cross Biotech Pty Ltd. | Production of proteins in active forms |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| CA1286591C (en) | 1987-12-18 | 1991-07-23 | Douglas B. Taylor | Apparatus for opening and closing roll-up door |
| US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| JPH01216939A (ja) | 1988-02-24 | 1989-08-30 | Hoechst Japan Kk | 末熟児頭蓋内出血阻止剤 |
| US4945086A (en) | 1988-05-03 | 1990-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Smooth muscle cell growth inhibitor |
| US5955336A (en) | 1988-08-17 | 1999-09-21 | Toyo Boseki Kabushiki Kaisha | DNA sequence for uricase and manufacturing process of uricase |
| GB8824591D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
| US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
| JP3148208B2 (ja) | 1988-10-31 | 2001-03-19 | 富士ゼロックス株式会社 | マルチ出力トレイ付プリントサーバおよびプリントシステム |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5010183A (en) | 1989-07-07 | 1991-04-23 | Macfarlane Donald E | Process for purifying DNA and RNA using cationic detergents |
| US5382518A (en) | 1989-07-13 | 1995-01-17 | Sanofi | Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells |
| NZ234453A (en) | 1989-07-13 | 1993-01-27 | Sanofi Sa | Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith |
| JPH0354581A (ja) | 1989-07-24 | 1991-03-08 | Nec Corp | 電子写真系プリンタの現像カートリッジ |
| US5286637A (en) | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
| DE69032406T2 (de) | 1989-08-23 | 1998-10-29 | Zvi Fuks | Wundheilmittel enthaltend heparanase |
| JPH03148298A (ja) | 1989-11-01 | 1991-06-25 | Sumitomo Pharmaceut Co Ltd | 修飾ペプチドおよびその製造方法 |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US5653974A (en) | 1990-10-18 | 1997-08-05 | Board Of Regents,The University Of Texas System | Preparation and characterization of liposomal formulations of tumor necrosis factor |
| DK0575545T3 (da) | 1991-03-15 | 2003-09-15 | Amgen Inc | Pegylering af polypeptider |
| CA2112674C (en) | 1991-07-02 | 2005-10-04 | John S. Patton | Method and device for delivering aerosolized medicaments |
| YU66892A (sh) | 1991-08-20 | 1995-10-24 | Hoechst Ag. | Fosfoinositolglikan - peptid sa delovanjem kao insulin |
| JP3148298B2 (ja) | 1991-09-02 | 2001-03-19 | 帝人株式会社 | 軽量複合成形物の製造法 |
| US5298643A (en) | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
| US5321095A (en) | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
| WO1994019007A1 (en) | 1993-02-16 | 1994-09-01 | Enzon, Inc. | Ribosome inactivating protein compositions having reduced antigenicity |
| US6385312B1 (en) | 1993-02-22 | 2002-05-07 | Murex Securities, Ltd. | Automatic routing and information system for telephonic services |
| JP3875730B2 (ja) | 1993-02-22 | 2007-01-31 | サノフィ・アベンティス株式会社 | 自己免疫疾患の予防治療剤 |
| US5298410A (en) | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
| JPH06255079A (ja) | 1993-03-08 | 1994-09-13 | Akira Totsuka | 被服地のスクリーン印刷装置及び被服地のスクリーン印刷方法 |
| US5783421A (en) | 1993-04-09 | 1998-07-21 | Bio-Technology General Corp. | DNA encoding novel polypeptide having Factor Xa inhibitory activity |
| JPH08511157A (ja) | 1993-04-09 | 1996-11-26 | バイオ − テクノロジー・ジェネラル・コーポレーション | Ｘａファクター阻害活性を有する新規ポリペプチド |
| WO1994023740A1 (en) | 1993-04-22 | 1994-10-27 | Celtrix Pharmaceuticals, Inc. | Conjugates of growth factor and bone resorption inhibitor |
| AU7113594A (en) | 1993-06-21 | 1995-01-17 | Enzon, Inc. | Site specific synthesis of conjugated peptides |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| WO1995011987A1 (en) | 1993-10-29 | 1995-05-04 | Incyte Pharmaceuticals, Inc. | Chimeric proteins including protease nexin-1 variants |
| KR960705579A (ko) | 1993-11-10 | 1996-11-08 | 에릭에스. 딕커 | 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates) |
| US5795776A (en) * | 1994-03-22 | 1998-08-18 | Bio-Technology General Corp. | Expression plasmids regulated by an OSMB promoter |
| FI96317C (fi) | 1994-05-31 | 1996-06-10 | Exavena Oy | Menetelmä hienojakoisten ja muunnettujen tärkkelyksien valmistamiseksi |
| DE4423131A1 (de) | 1994-07-01 | 1996-01-04 | Bayer Ag | Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4 |
| US5633227A (en) | 1994-09-12 | 1997-05-27 | Miles, Inc. | Secretory leukocyte protease inhibitor as an inhibitor of tryptase |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| CN1168694A (zh) | 1994-12-07 | 1997-12-24 | 诺沃挪第克公司 | 具有减弱的变应原性的多肽 |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| IL116696A (en) | 1995-01-25 | 1999-08-17 | Bio Technology General Corp | Production of enzymatically active recombinant carboxypeptidase b |
| TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| FR2733914B1 (fr) | 1995-05-11 | 1997-08-01 | Sanofi Sa | Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation |
| JPH09154581A (ja) | 1995-12-05 | 1997-06-17 | Asahi Chem Ind Co Ltd | ウリカーゼを生産する実質上純粋な微生物 |
| US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| ATE342729T1 (de) | 1997-01-15 | 2006-11-15 | Phoenix Pharmacologics Inc | Modifizierter tumor-nekrosefaktor |
| US5816397A (en) | 1997-01-21 | 1998-10-06 | Ogio International, Inc. | Golf club carrying apparatus |
| EP1017794A1 (en) | 1997-02-06 | 2000-07-12 | Novo Nordisk A/S | Polypeptide-polymer conjugates having added and/or removed attachment groups |
| KR100369838B1 (ko) | 1997-02-26 | 2003-09-29 | 주식회사 엘지생명과학 | 한국형c형간염바이러스의비구조단백질3에서유래한단백질분해효소단백질및그의제조방법 |
| US6821763B2 (en) | 1997-07-04 | 2004-11-23 | Ajinomoto Co., Inc. | Process for producing microbial transglutaminase |
| JPH1175876A (ja) * | 1997-07-04 | 1999-03-23 | Ajinomoto Co Inc | 新規な微生物トランスグルタミナーゼの製造法 |
| ATE274522T1 (de) | 1998-06-01 | 2004-09-15 | Genentech Inc | Abtrennung von antikörper-monomeren von deren multimeren mittels ionaustausch-chromatographie |
| PT2158923E (pt) | 1998-08-06 | 2013-06-04 | Univ Duke | Conjugados de peg-urato oxidase e sua utilização |
| US20060188971A1 (en) | 1998-08-06 | 2006-08-24 | Duke University | Urate oxidase |
| US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| KR100488848B1 (ko) * | 1998-08-06 | 2005-05-11 | 듀크 유니버서티 | 피이지-유레이트 옥시데이즈 접합체 및 그의 이용 |
| ES2352451T3 (es) | 1998-08-06 | 2011-02-18 | Duke University | Urato oxidasa. |
| US6425448B1 (en) | 2001-01-30 | 2002-07-30 | Cdx Gas, L.L.P. | Method and system for accessing subterranean zones from a limited surface area |
| US6429860B1 (en) | 1999-06-15 | 2002-08-06 | Visicomp, Inc. | Method and system for run-time visualization of the function and operation of a computer program |
| JP5219322B2 (ja) | 2000-02-14 | 2013-06-26 | クリニカル ディシジョン サポート，エルエルシー | 自動診断システムおよび方法 |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| US20050084478A1 (en) | 2000-10-17 | 2005-04-21 | Chih-Ping Liu | Combination therapy using interferon-tau |
| WO2002070007A1 (en) | 2001-03-02 | 2002-09-12 | Medimmune, Inc. | Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists |
| US6913915B2 (en) | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
| AU2002365360A1 (en) | 2001-11-28 | 2003-06-10 | Biopolymed Inc. | Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same |
| ATE364092T1 (de) | 2003-01-09 | 2007-06-15 | Genentech Inc | Reinigung von polypeptiden |
| JP4273998B2 (ja) | 2004-02-26 | 2009-06-03 | 学校法人東海大学 | プロテオーム解析用試料の調製方法 |
| WO2005110386A2 (en) | 2004-04-13 | 2005-11-24 | Wisconsin Alumni Research Foundation | Method of decreasing inflammation in kidney transplantation using angiotensin receptor blockers |
| CN103088038B (zh) | 2004-07-12 | 2015-06-24 | 美国天甲生物医药有限公司 | 黄病毒疫苗 |
| GB0420888D0 (en) | 2004-09-20 | 2004-10-20 | Photopharmica Ltd | Compounds and uses |
| NZ562292A (en) | 2005-04-11 | 2009-11-27 | Savient Pharmaceuticals Inc | Variant forms of urate oxidase and use thereof |
| AU2006235437B2 (en) | 2005-04-11 | 2011-11-24 | Horizon Therapeutics Usa, Inc. | A variant form of urate oxidase and use thereof |
| US9534013B2 (en) | 2006-04-12 | 2017-01-03 | Horizon Pharma Rheumatology Llc | Purification of proteins with cationic surfactant |
| US20080159976A1 (en) | 2005-04-11 | 2008-07-03 | Jacob Hartman | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
| US8148123B2 (en) | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
| CA2642656A1 (en) | 2006-02-22 | 2007-09-07 | Novartis Pharma Ag | System for delivering nebulized cyclosporine and methods of treatment |
| NL1031926C2 (nl) | 2006-05-31 | 2007-12-03 | X Flow Bv | Inrichting met een bioreactor en membraanfiltratiemodule voor het behandelen van een inkomend fluïdum. |
| EP2100122A4 (en) | 2006-11-21 | 2010-01-06 | Univ Southern California | TESTS FOR THE DETECTION OF POLY (ETHYLENE GLYCOL) ANTIBODIES AND KITS FOR IMPLEMENTATION |
| EP2210600B1 (en) | 2007-10-10 | 2017-11-29 | Kyowa Hakko Bio Co., Ltd. | Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine |
| CN101168052A (zh) | 2007-10-26 | 2008-04-30 | 西安交通大学 | 一种防治高尿酸血症及痛风的肠溶制剂 |
| TW201016208A (en) | 2008-09-15 | 2010-05-01 | Elan Pharm Inc | Methods of treatment of hyperuricemia and associated disease states |
| WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| EP2446260B1 (en) | 2009-06-25 | 2018-12-26 | Horizon Pharma Rheumatology LLC | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| WO2011032175A1 (en) | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
| JP5451464B2 (ja) | 2010-03-09 | 2014-03-26 | キヤノン株式会社 | 帯電装置 |
| EP3659601A1 (en) | 2010-03-30 | 2020-06-03 | Ardea Biosciences, Inc. | Treatment of gout |
| EA201490928A1 (ru) | 2011-11-04 | 2014-11-28 | Саймабэй Терапьютикс, Инк. | Способы лечения острых приступов подагры |
| JP5746101B2 (ja) | 2012-06-18 | 2015-07-08 | コスメディ製薬株式会社 | マイクロニードルの迅速溶解法 |
| GB2512876A (en) | 2013-04-09 | 2014-10-15 | Image Analysis Ltd | Methods and apparatus for quantifying inflammation |
| PT3126330T (pt) | 2014-04-04 | 2019-04-29 | Pfizer | Compostos bicíclicos de heteroarilo ou arilo fusionados e a sua utilização como inibidores de irak4 |
| IL318183A (en) | 2016-03-11 | 2025-03-01 | Selecta Biosciences Inc | Formulations and doses of pegylated uricase |
| WO2018007878A1 (en) | 2016-07-05 | 2018-01-11 | CanTrust LifeScience Corp. | Methods of treating and preventing gout and lead nephropathy |
| EP3538135A4 (en) | 2016-11-11 | 2020-07-29 | Horizon Pharma Rheumatology LLC | POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES |
| US20220409620A1 (en) | 2016-11-11 | 2022-12-29 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| AU2018236123B2 (en) | 2017-03-11 | 2024-04-18 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| WO2020160325A1 (en) | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| WO2020160324A1 (en) | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| US12121566B2 (en) | 2019-01-30 | 2024-10-22 | Horizon Therapeutics Usa, Inc. | Methods for treating gout |
| WO2021042055A1 (en) | 2019-08-30 | 2021-03-04 | Horizon Pharma Rheumatology Llc | Pegloticase for treatment of gout in renal transplant recipients |
| EP4192581A4 (en) | 2020-08-10 | 2024-09-25 | Horizon Therapeutics USA, Inc. | METHODS OF TREATING GOUT |
-
2006
- 2006-04-11 NZ NZ562292A patent/NZ562292A/en not_active IP Right Cessation
- 2006-04-11 RU RU2007141625/10A patent/RU2451074C2/ru not_active IP Right Cessation
- 2006-04-11 SI SI200632400T patent/SI3321359T1/sl unknown
- 2006-04-11 HU HU0700730A patent/HU229068B1/hu active Protection Beyond IP Right Term
- 2006-04-11 ES ES17192971T patent/ES2856881T3/es active Active
- 2006-04-11 BR BRPI0612941-2A patent/BRPI0612941A2/pt not_active Application Discontinuation
- 2006-04-11 CN CN2006800210183A patent/CN101198693B/zh active Active
- 2006-04-11 HU HUE17192971A patent/HUE052976T2/hu unknown
- 2006-04-11 PL PL387691A patent/PL215285B1/pl unknown
- 2006-04-11 EP EP20060749889 patent/EP1871874B1/en active Active
- 2006-04-11 KR KR20077026113A patent/KR20080009111A/ko not_active Ceased
- 2006-04-11 CA CA 2604399 patent/CA2604399A1/en not_active Abandoned
- 2006-04-11 DK DK17192971.4T patent/DK3321359T3/da active
- 2006-04-11 US US11/918,297 patent/US8188224B2/en active Active
- 2006-04-11 PT PT171929714T patent/PT3321359T/pt unknown
- 2006-04-11 SG SG201002407-3A patent/SG161247A1/en unknown
- 2006-04-11 CZ CZ20070695A patent/CZ2007695A3/cs unknown
- 2006-04-11 EP EP15156612.2A patent/EP2947145A1/en not_active Withdrawn
- 2006-04-11 ES ES06749889.9T patent/ES2538357T3/es active Active
- 2006-04-11 MX MX2007012547A patent/MX2007012547A/es active IP Right Grant
- 2006-04-11 AU AU2006235495A patent/AU2006235495B2/en active Active
- 2006-04-11 PL PL17192971T patent/PL3321359T3/pl unknown
- 2006-04-11 EP EP17192971.4A patent/EP3321359B1/en active Active
- 2006-04-11 WO PCT/US2006/013660 patent/WO2006110819A2/en not_active Ceased
- 2006-04-11 TW TW095112937A patent/TWI366467B/zh active
- 2006-04-11 JP JP2008505664A patent/JP2008535500A/ja active Pending
- 2006-04-11 LT LTEP17192971.4T patent/LT3321359T/lt unknown
-
2007
- 2007-10-09 IL IL186510A patent/IL186510A/en active IP Right Grant
- 2007-10-10 ZA ZA200708650A patent/ZA200708650B/xx unknown
-
2012
- 2012-02-20 RU RU2012106150/10A patent/RU2012106150A/ru not_active Application Discontinuation
- 2012-02-20 RU RU2012106116A patent/RU2610680C9/ru not_active IP Right Cessation
- 2012-02-20 RU RU2012106148/10A patent/RU2012106148A/ru not_active Application Discontinuation
- 2012-05-01 US US13/461,170 patent/US8541205B2/en active Active
-
2013
- 2013-01-23 JP JP2013009968A patent/JP2013135676A/ja not_active Withdrawn
- 2013-08-21 US US13/972,167 patent/US9017980B2/en active Active
-
2015
- 2015-01-07 JP JP2015001805A patent/JP2015107122A/ja active Pending
- 2015-03-27 US US14/671,246 patent/US9670467B2/en active Active
- 2015-10-07 FR FR15C0067C patent/FR15C0067I2/fr active Active
-
2016
- 2016-07-04 JP JP2016132216A patent/JP2016171819A/ja not_active Withdrawn
-
2017
- 2017-04-18 US US15/490,736 patent/US20170298326A1/en not_active Abandoned
- 2017-07-13 US US15/649,398 patent/US20170313993A1/en not_active Abandoned
- 2017-07-13 US US15/649,462 patent/US9926537B2/en active Active
- 2017-07-13 US US15/649,488 patent/US9926538B2/en active Active
- 2017-07-13 US US15/649,478 patent/US10160958B2/en active Active
- 2017-10-18 JP JP2017201898A patent/JP2018015005A/ja active Pending
-
2018
- 2018-11-28 US US16/202,743 patent/US10731139B2/en active Active
-
2019
- 2019-01-04 JP JP2019000199A patent/JP2019070006A/ja active Pending
-
2020
- 2020-06-24 US US16/911,074 patent/US11345899B2/en active Active
-
2021
- 2021-03-02 CY CY20211100173T patent/CY1124138T1/el unknown
-
2022
- 2022-04-19 US US17/724,091 patent/US11781119B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012106116A (ru) | Вариантные формы уратоксидазы и их применение | |
| US11472842B2 (en) | Analogues of hepcidin mimetics with improved in vivo half lives | |
| HRP20240135T1 (hr) | Fgf21 mutanti i njihove upotrebe | |
| NZ611324A (en) | Il-17 binding proteins | |
| JP2018015005A5 (ru) | ||
| JP2013520426A5 (ru) | ||
| IN2014CN02050A (ru) | ||
| RU2013128896A (ru) | Сконструированные белки повторов, которые связываются с сывороточным альбумином | |
| EP1801206A4 (en) | PROCESS FOR THE PREPARATION OF L-ARGININE, L-ORNITHIN OR L-CITRULLINE | |
| EP2625191A1 (en) | A thermo-responsive polymer covalently bound with a peptide | |
| RU2009113562A (ru) | Модификации пептидов, происходящих из купредоксина, и способы их применения | |
| EA200701234A1 (ru) | Конъюгаты инсулиноподобного фактора роста i (ифр-i) и полиэтиленгликоля | |
| JP2003321500A (ja) | 新規なポリペプチドおよびその製造方法 | |
| ATE485386T1 (de) | Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen | |
| WO2022235923A3 (en) | Peptide-lipid conjugates | |
| WO2002068608A3 (en) | Sulfated ccr5 peptides for hiv-1 infection | |
| SI2952521T1 (en) | Peptides derived from human BPLP protein, polynucleotides encoding these peptides, and antibodies directed against these peptides | |
| RU2016134328A (ru) | Конъюгаты фактора свёртывания крови vii | |
| TW200505943A (en) | Polypeptide | |
| WO2006028561A3 (en) | Novel purified fabi polypeptides from fransicella tularensis | |
| JP7489319B2 (ja) | 細胞膜透過性ペプチド | |
| DE602005025141D1 (de) | In Zellen eindringende Peptide als Träger für Moleküle | |
| DE69117965D1 (de) | Peptide, welche hiv-retroviren-hemmende antikörper induzieren, sowie gegen diese peptide gerichtete antikörper | |
| EP1842911A4 (en) | HLA BINDING PEPTIDES, FOR THOSE CODING DNA FRAGMENTS AND RECOMBINANT VECTORS | |
| ATE521635T1 (de) | Physiologisch wirksamer komplex mit tnf aktivität |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant | ||
| TK4A | Correction to the publication in the bulletin (patent) |
Free format text: CORRECTION TO CHAPTER -FG4A- IN JOURNAL 5-2017 FOR INID CODE(S) (24) |
|
| TH4A | Reissue of patent specification | ||
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20190412 |